“Respiratory Infections, Lung Cancer, Heart Disease…” Over 80% of premature deaths caused by small smoke particles in the United States result directly from human-ignited fires. This is the outcome of a study published today (January 16, 2023) in IOP…
The U.S. Food and Drug Administration approved Mirati Therapeutics Inc’s lung cancer drug adagrasib, the company said on Monday, sending its shares up more than 8% in extended trading. Mirati’s drug has been approved for treating adult patients with…
Two decades of I-ELCAP follow-up data show 80% lung cancer-specific survival rate CHICAGO – The diagnosis of early-stage lung cancer with low-dose CT (LDCT) screening led to high rates of lung cancer-specific survival two decades later, according to I-ELCAP…
By Angus Liu In a potential key battleground for KRAS inhibitors that involves combination with Merck’s PD-1 king Keytruda, Mirati Therapeutics’ adagrasib appears to be pulling ahead of Amgen’s first-to-market Lumakras in the latest clinical data revelation. And Mirati’s…
by Karen Weintraub Lung cancer screening has been proven to save lives. But according to a new study, only 5.8% of people eligible for a free, low-dose CT scan actually get screened for lung cancer—far below levels seen for…
Medical News Today, By Deep Shukla Lung cancer is the second most commonly diagnosed cancer worldwide and the leading cause of cancer deaths. About 80–85% of all lung cancer cases belong to a category known as non-small cell lung…
GSK’s anti-TIM-3 antibody is moving into a pivotal trial after hitting the mark in the midphase portion of the study, cementing the Big Pharma’s status as a front-runner in a thinning field featuring Novartis. TIM-3 is a checkpoint receptor…
The FDA has granted a fast track designation to sapanisertib (CB-228) for adult patients with unresectable or metastatic squamous non–small cell lung cancer (NSCLC) who harbor a mutation in nuclear factor erythroid 2-related factor (NRF2) and have received prior…
The FDA granted regular approval to selpercatinib for treatment of certain patients with non-small cell lung cancer (NSCLC). The indication applies to use of selpercatinib (Retevmo, Eli Lilly) by adults with locally advanced or metastatic RET fusion-positive NSCLC as…
In a closely watched competition among KRAS inhibitors, Amgen leads the pack with a randomized trial win in lung cancer. Now, the California drugmaker is giving a first look at the detailed data that could set the bar for…